Autoimmunity, Antibody, Autoimmune disease, Immune system, Autoimmune diseases, Drug
Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca
Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca https://t.co/G8rcOAm6e1 with @realJacobBell $VIE $HZNP $AZN
OpenAstraZeneca's decision to spin out Viela Bio in 2018 paid off with a drug approval, an initial public offering, and now an acquisition that will net the pharma close to $800 million.
Horizon acquires Viela Bio for $3B in a windfall for AstraZeneca https://t.co/G8rcOAm6e1 with @realJacobBell $VIE $HZNP $AZN
OpenHorizon acquires Viela Bio for $3B in a windfall for AstraZeneca
AstraZeneca's decision to spin out Viela Bio in 2018 paid off with a drug approval, an initial public offering, and now an acquisition that will net the pharma close to $800 million.
We are sorry, we could not find the related article
If you are curious about Biotech Essentials, the Influencers Review and Startups
Please click on:
Or signup to our newsletters
Other Essentials
AI Essentials
Robotics
Robotics
Ethics
Ethics
Research
Research
Applied Use Cases
Applied Use Cases
Marketing
Marketing
Healthcare
Healthcare
Cybersecurity
Cybersecurity
Horizon inks $3B deal to buy AstraZeneca spinout Viela for autoimmune drugs
Horizon Therapeutics has struck a $3 billion deal to buy AstraZeneca spinout Viela Bio. The takeover will give Horizon a clutch of clinical-phase autoimmune and inflammatory disease drug ...
Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio
- Conference Call Today at 8 a.m. EST to Discuss Transaction -- Provides TEPEZZA® (teprotumumab-trbw) Supply Update; Submitted Prior Approval Supplement to FDA to Support Increased Scale ...
Swiss Biotech Launches Amidst Hot Streak for Rare Autoimmune Disease
Swiss biotech Chord Therapeutics launched this week with a €13.7M Series A, becoming the latest company to tackle the rare condition neuromyelitis optica, for which three therapies have ...
Momenta shift to new drugs pays off with $6.5 billion J&J buyout
Once a leader in biosimilar development, Momenta pivoted toward developing treatments for autoimmune diseases, including one that drew J&J's interest.
Gaining momentum, Johnson & Johnson acquires Momenta for $6.5B cash
The pace of biopharma mergers and acquisitions has quickened with Johnson & Johnson’s $6.5 billion all-cash acquisition of Momenta Pharmaceuticals Inc. Bringing Momenta into the fold ...
Advances in the Battle Against Autoimmune Disease
Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.
AstraZeneca to Acquire Alexion for $39B, Adding Rare Disease, Immunology Assets
AstraZeneca signaled its intent to expand into rare disease drug development and grow into an immunology leader on Saturday when it announced plans to acquire Alexion Pharmaceuticals for ...
Viela Bio Shares Rise 52% on $3.05 Billion Buyout by Horizon Therapeutics
Shares of Viela Bio traded higher after it was announced that the company entered into a definitive agreement to be acquired by Horizon Therapeutics for $53.00 per share.
Association between autoimmune diseases and COVID-19 as assessed in both a test-negative case–control and population case–control design
COVID-19 epidemic has paralleled with the so called infodemic, where countless pieces of information have been disseminated on putative risk factors for COVID-19. Among those, emerged the ...
Top 20 Biopharma M&A of 2020 by Total Deal Value
#post_contentBiopharma merger and acquisition activity in 2020 was mainly filled with late-stage, bolt-on acquisitions, which were orders of magnitude smaller than the mega M&A deals of ...
Bio Roundup: Rare Disease Showdowns, Prices on TV, Dealmania & More
The market for drugs for rare or “orphan” diseases continues to grow. An April report from Evaluate Pharma predicted sales of orphan drugs to rise 12
The top 5 pharma M&A deals of 2020
2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% ...
What Are Common Symptoms of Autoimmune Disease?
Fatigue, joint pain and skin problems are some symptoms of autoimmune diseases.